CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved.

Anti-obesity medication

AU market earnings: ResMed's robust performance

ResMed reports a significant revenue rise of 9% to $1.22 billion USD in the June quarter, highlighting its strong market position despite concerns over weight loss drugs impacting product demand.

2024-08-05T08:13:42+0100

Macro Intelligence: weight-loss drugs drive big pharma

After an initial negative reaction to the weight-loss drug thematic, ResMed says the trend will boost demand for its products. However, with alcohol consumption amongst GLP-1 patients waning, beverage companies could suffer.

2024-05-08T01:11:22+0100

This website is owned and operated by IG Bank S.A. Registered address at 42 Rue du Rhone, 1204 Geneva, authorised and regulated by FINMA.

The information on this site is not directed at residents of the United States and Belgium, or any particular country outside Switzerland and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

TOP PARTNER

IG Group | Careers

Anti-obesity medication

Article result template

AU market earnings: ResMed's robust performance

Macro Intelligence: weight-loss drugs drive big pharma

Markets

CFD trading

Trading platforms

Market insight

Contact us